# A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants

> **NCT07466550** · PHASE1 · NOT_YET_RECRUITING · sponsor: **AbbVie** · enrollment: 60 (estimated)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** Risankizumab
- **DRUG:** Risankizumab

## Key facts

- **NCT ID:** NCT07466550
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-08
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07466550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07466550, "A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07466550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*